HC Wainwright began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX – Free Report) in a report released on Thursday, Marketbeat reports. The firm issued a neutral rating on the stock.
Avalo Therapeutics Trading Up 13.6 %
Avalo Therapeutics stock opened at $13.20 on Thursday. The stock has a 50 day moving average of $9.36 and a 200-day moving average of $11.25. Avalo Therapeutics has a 52 week low of $3.95 and a 52 week high of $34.46.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). On average, analysts forecast that Avalo Therapeutics will post -7.78 earnings per share for the current year.
Institutional Trading of Avalo Therapeutics
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Stories
- Five stocks we like better than Avalo Therapeutics
- How to Read Stock Charts for Beginners
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Investors Need to Know About Upcoming IPOs
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- How to Use the MarketBeat Excel Dividend Calculator
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.